16 Sep 2026

CRC Research Update — September 16, 2026

Creator: The CRC Digest
Published: 2026-09-16T11:30:35Z

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

SCREENING
Systematic review finds screening gaps in early-onset colorectal cancer despite lowered age thresholds
A systematic review of population-based screening studies found that current strategies may not adequately address the diagnostic burden of colorectal cancer in adults younger than 50, even as several countries have lowered the recommended screening age to 45 years. (Cancer Epidemiol)
RESEARCH
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection, though the review notes that prognostic validity alone does not establish treatment-decision utility. (J Gastrointest Cancer)
TREATMENT
Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors
A phase 1 dose-escalation trial evaluated GFH375, an oral compound that targets both active and inactive states of KRAS G12D proteins, in patients with advanced solid tumors harboring the KRAS G12D mutation, including colorectal cancer. (Nat Med)
RESEARCH
Study identifies FAIM2 pathway in cancer-associated fibroblasts linked to immune resistance in MSS colorectal cancer
Researchers identified Fas apoptotic inhibitory molecule 2 (FAIM2) as a stromal regulator downregulated in microsatellite-stable colorectal cancer, where it inversely correlates with collagen production in cancer-associated fibroblasts and is associated with immune infiltration and patient prognosis. (Mol Cell Biochem)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Screening strategies may not adequately address early-onset CRC burden
A systematic review found uncertainty remains regarding whether current screening strategies adequately address the diagnostic burden of early-onset colorectal cancer, defined as diagnosis before age 50. (Cancer Epidemiol)

💙 Living with CRC

Survivorship, quality of life, and supportive care

Phase II trial examines quality of life with panitumumab-based intensified regimen
The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a specific toxicity profile including skin toxicity. (Eur J Cancer)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial
GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)
Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response
A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res)
Critical review outlines biomarker-guided treatment selection in metastatic CRC
A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol)

Today's research spans screening effectiveness in younger adults, molecular residual disease monitoring, and targeted therapies for specific genetic subtypes.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest